“…Our in vitro results are in keeping with two recent reports of short-term immunological and virological efficacy of INI-containing regimens in two heavily pretreated HIV-2- HIV-2 susceptibility to integrase inhibitors infected patients. 31,32 Due to the few number of active antiretroviral drugs available for the treatment of HIV-2-infected patients, this new class of antiretroviral drugs might represent a new therapeutic option for HIV-2-infected patients, which remains to be evaluated through multicentre trials. …”